Central nervous system injury

TORONTO and HAIFA, Israel, Sept. 12, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicine i market , is pleased to announce its participation in a series of prestigious conferences this October. These events will showcase the Company’s advancements in exosome therapy, reinforce its commitment to driving innovation in regenerative medicine, and increase visibility with major pharmaceutical companies. In October, NurExone will sponsor and present at the World Orphan Drug Congress in Barcelona from October 22-25, 2024. This prominent event unites global leaders in orphan drug development and rare diseases with a focus on strategy, advocacy and partnerships. NurExone will highlight its cutting-edge work in exosome-based therapies aimed at regeneration of neurons in the central nervous system leading to recovery of motor function after acute spinal cord injuries. Notably, NurExone is one of a small number of companies to receive Orphan Drug Designation for acute spinal cord injury. ii Additionally, Dr. Noa Avni, research and development director of NurExone, will present at the Precision EV Forum 2024 in Cambridge, UK, from October 22-23, 2024 (“EV” refers to “Extracellular Vesicles”). She will present in the session titled ‘Approaching Translational Challenges for Therapeutic EVs,’ addressing key hurdles in bringing EV-based therapies to clinical applications, presenting NurExone’s unique technology and potential. Furthermore, NurExone will chair the ‘Plenary Session: Production of EVs Under GMP Conditions’, sharing its learnings and capabilities in transferring technology to scaled GMP-compliant EV production for therapeutic use. Lastly, NurExone will be presenting at the Israeli Society of Gene and Cell Therapy’s (ISGCT 2024) meeting in September in Israel. As gene and cell therapy gain momentum globally, NurExone is proud to participate alongside other leading Israeli researchers who are making significant contributions to advancements in stem cell research, genome editing, and T cell engineering. As previously announced, NurExone’s Chief Executive Officer, Dr. Lior Shaltiel, will also speak at the Bioprocess International Conference in Boston, taking place from September 23-26, 2024. At this leading industry event, Dr. Shaltiel will present the Company’s groundbreaking ExoPTEN nanodrug, a potential treatment for acute spinal cord injuries and other central nervous system conditions, including glaucoma. This appearance highlights NurExone’s growing influence in the field of exosome-based therapies for clinical applications. Dr. Shaltiel commented: “through our strategy of active engagement in prestigious industry conferences we aim to advance therapeutic exosomes and help address the critical challenges that currently exist in the development landscape for central nervous system diseases. These events provide invaluable opportunities to meet with industry peers, present the Company’s achievements and explore potential collaborations as we expand the therapeutic potential of ExoPTEN across additional indications. We are proud to share our progress and vision with the global scientific community.” About NurExone NurExone Biologic Inc. is a TSX Venture Exchange (“ TSXV ”) and OTCQB listed pharmaceutical company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. For additional information, please visit or follow NurExone on LinkedIn , Twitter , Facebook , or YouTube . For more information, please contact: Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com Thesis Capital Inc. Investor Relations - Canada Phone: +1 905-347-5569 Email: IR@nurexone.com Dr. Eva Reuter Investor Relations - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu Allele Capital Partners Investor Relations - US Phone: +1 978-857-5075 Email: aeriksen@allelecapital.com FORWARD-LOOKING STATEMENTS This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to the Company presenting at the upcoming conferences, the focus of the presentations and the intended outcome of the presentations; the presenters at the conferences; the Company’s ExoPTEN nanodrug being a potential treatment for acute spinal cord injuries and other central nerve system indications; the Company engaging with collaboration partners, industry leaders, researchers and innovators; and the NurExone platform technology offering novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including the general business and economic conditions of the industries and countries in which we operate; the general market conditions; the ability to secure additional funding; partnerships having their intended impact on the Company and its business; patents safeguarding NurExone’s technology; the Company’s drug products having its intended benefits and effects; the Company making progress through new partnerships and technologies to move towards commercialization of their products; the Company’s intellectual property and technology being novel and inventive; the intellectual property having the intended impact on the Company and its business; exosomes becoming an ideal and natural choice for drug delivery; the Company making advancements in the manufacturing process of exosomes; exosomes holding immense promise for regenerative medicine; the Company’s production methods continuing to be reliable; the Company will have flexibility in optimizing its exosome production method; exosomes will serve as an excellent, targeted system for drug delivery; the Company will pave the way to regenerative medicine treatments for a variety of clinical indications by the Company and with future collaboration partners; the Company will present at the upcoming conferences, focus the presentations on the subject matter indicated herein and the presentations will have their intended outcomes on the Company and its business; the Company’s ExoPTEN nanodrug being a potential treatment for acute spinal cord injuries and other central nerve system indications; the Company will engage with collaboration partners, industry leaders, researchers and innovators; and the NurExone platform technology offering novel solutions to drug companies. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to the Company’s early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; protection of the Company’s intellectual property; dependence on the Company’s strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; the NurExone platform technology being unable to offer novel solutions to drug companies; risks that the Company’s intellectual property and technology won’t have the intended impact on the Company and/or its business; the Company’s inability to realize upon partnerships; risk that the exosomes will not become an ideal and/or natural choice for drug delivery; risk that the company will be unable to make advancements in the manufacturing process of exosomes; risk that exosomes will not be a viable option in regenerative medicine; risk that the Company’s production methods will become unreliable; risk that the Company will not have flexibility in optimizing its exosome production method; risk that exosomes will not serve as a targeted system for drug delivery; risk that the Company will be unable to pave the way to regenerative medicine treatments for a variety of clinical indications by the Company and/or with future collaboration partners; risk that the Company will be unable to present at the upcoming conferences, the subject matter of the presentations will change and/or the presentations will not have the intended outcome on the Company and/or its business; risk that the Company’s ExoPTEN nanodrug will not work as a potential treatment for acute spinal cord injuries and/or other central nerve system indications; risk that the Company will be unable to engage with collaboration partners, industry leaders, researchers and/or innovators at the conferences or at all; risk that the NurExone platform technology will be unable to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications; and the risks discussed under the heading “Risk Factors” on pages 29 to 36 of the Company’s Annual Information Form dated March 30, 2023, a copy of which is available under the Company’s SEDAR+ pro . These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law. Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. ______________________________ i ii

TORONTO and HAIFA, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”) is pleased to announce compelling new findings that highlight the therapeutic potential of ExoPTEN for patients with spinal cord injuries. In a recent preclinical study using a spinal cord compression model, our team demonstrated that ExoPTEN has a strong ability to target and accumulate at the injury site, even when administered up to one week after the injury occurred. This finding is crucial because it suggests a long window of time in which treatment can be effectively administered. Dr. Lior Shaltiel, NurExone Chief Executive Officer, emphasized the real-world significance of this capability by stating that “the ability to treat patients up to 7 days post-injury could broaden the range of patients eligible for treatment and extend the window of effectiveness, leading to enhanced recovery. Moreover, the findings can enhance significantly the ability to recruit more patients to clinical trials and to expand the numbers of treatable patients, without being limited by a short therapeutic window and hospital administration challenges." He continued, "With the global incidence of spinal cord injury estimated between 250,000 and 500,000i cases annually and given that some patients do not receive immediate treatment, the potential market for a therapy effective up to 1-week post-injury could be substantial." As shown in Figure 1, the ExoPTEN was labelled with a fluorescent mark and administered to rats with induced spinal cord compression injuries. The administration was conducted at four different time points: on the day of injury (day 0), 3 days later, 5 days later, and 7 days later, and compared to each other and to an untreated control group. The goal was to evaluate how well ExoPTEN targets and accumulates at an injury site over time. Using an advanced In Vivo Imaging System (“IVIS”), it was observed that ExoPTEN consistently accumulated at the injury site. A notable gradient of homing capacity was observed, with later administration times resulting in progressively higher levels of accumulation. The highest accumulation was seen in those treated 7 days post-injury with a statistically significant dose-dependent accumulation of ExoPTEN at the injury site. These results underscore the exceptional homing capacity of ExoPTEN, even 7 days post-injury, suggesting a broad therapeutic window for intervention. This creates new possibilities for the timing and flexibility of treatment, enhancing the potential for recovery in patients with spinal cord injuries. Dr. Noa Avni, Director of research and development stated that “we are excited about the implications of these findings for our phase I/II clinical trial design and patient care. The extended therapeutic window we have demonstrated not only highlights the potency of our exosome-based therapy but also offers hope for adaptable treatment regimens in clinical settings." Figure 1: Quantification and Distribution of ExoPTEN in Rat Spinal Cords Following Minimal-Invasive Administration Post-Spinal Cord Injury About NurExone NurExone Biologic Inc. is a TSX Venture Exchange (“TSXV”) and OTCQB listed pharmaceutical company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior ShaltielChief Executive Officer and DirectorPhone: +972-52-4803034Email: info@nurexone.com Thesis Capital Inc.Investor Relations - CanadaPhone: +1 905-347-5569Email: IR@nurexone.com Dr. Eva ReuterInvestor Relations - GermanyPhone: +49-69-1532-5857Email: e.reuter@dr-reuter.eu Allele Capital PartnersInvestor Relations - USPhone: +1 978-857-5075Email: aeriksen@allelecapital.com FORWARD-LOOKING STATEMENTS This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to the results and implications of the study; the timeframe for the administration of treatment and the potential eligibility of patients; the treatment leading to enhanced recovery; there being a broad therapeutic window for intervention; there being adaptable treatment regimens in clinical settings; the Company’s ExoPTEN nanodrug being a potential treatment for acute spinal cord injuries and other central nerve system indications; the Company engaging with collaboration partners, industry leaders, researchers and innovators; and the NurExone platform technology offering novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including the general business and economic conditions of the industries and countries in which we operate; the general market conditions; the ability to secure additional funding; partnerships having their intended impact on the Company and its business; patents safeguarding NurExone’s technology; the Company’s drug products having its intended benefits and effects; the Company making progress through new partnerships and technologies to move towards commercialization of their products; the Company’s intellectual property and technology being novel and inventive; the intellectual property having the intended impact on the Company and its business; exosomes becoming an ideal and natural choice for drug delivery; the Company making advancements in the manufacturing process of exosomes; exosomes holding immense promise for regenerative medicine; the Company’s production methods continuing to be reliable; the Company will have flexibility in optimizing its exosome production method; exosomes will serve as an excellent, targeted system for drug delivery; the Company will pave the way to regenerative medicine treatments for a variety of clinical indications by the Company and with future collaboration partners; the Company’s ExoPTEN nanodrug being a potential treatment for acute spinal cord injuries and other central nerve system indications; the Company will engage with collaboration partners, industry leaders, researchers and innovators; the study will yield its intended results and have its intended implications on the Company and its business; ExoPTEN will have a longer timeframe for the administration of treatment and therefore there will be additional eligible patients; the treatment will lead to enhanced recovery; there will be a broad therapeutic window for intervention; there will be an adaptable treatment regimens in clinical settings; and the NurExone platform technology offering novel solutions to drug companies. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to the Company’s early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; protection of the Company’s intellectual property; dependence on the Company’s strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; the NurExone platform technology being unable to offer novel solutions to drug companies; risks that the Company’s intellectual property and technology won’t have the intended impact on the Company and/or its business; the Company’s inability to realize upon partnerships; risk that the exosomes will not become an ideal and/or natural choice for drug delivery; risk that the company will be unable to make advancements in the manufacturing process of exosomes; risk that exosomes will not be a viable option in regenerative medicine; risk that the Company’s production methods will become unreliable; risk that the Company will not have flexibility in optimizing its exosome production method; risk that exosomes will not serve as a targeted system for drug delivery; risk that the Company will be unable to pave the way to regenerative medicine treatments for a variety of clinical indications by the Company and/or with future collaboration partners; risk that the Company’s ExoPTEN nanodrug will not work as a potential treatment for acute spinal cord injuries and/or other central nerve system indications; risk that the Company will be unable to engage with collaboration partners, industry leaders, researchers and/or innovators at the conferences or at all; risk that the NurExone platform technology will be unable to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications; risk that the study will not yield its intended results and/or have its intended implications on the Company and its business; risk that the timeframe for the administration of treatment will not be longer and/or will not lead to more eligible patients; risk that the treatment will not lead to enhanced recovery; risk that there will not be a broader therapeutic window for intervention; risk that there will not be adaptable treatment regimens in clinical settings; and the risks discussed under the heading “Risk Factors” on pages 29 to 36 of the Company’s Annual Information Form dated March 30, 2023, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law. Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. _____________________ihttps://iris.who.int/bitstream/handle/10665/94190/9789241564663_eng.pdf?sequence=1 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6349d08a-be42-434d-9a78-e2158d074d9b

TORONTO and HAIFA, Israel, Aug. 28, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce its financial and operational results for the three and six months ended June 30, 2024, the highlights of which are included in this news release. The Company’s complete set of condensed interim consolidated financial statements for the three and six months ended June 30, 2024, and accompanying management’s discussion and analysis for the period can be accessed by visiting the Company’s website at www.nurexone.com and its profile page on SEDAR+ at www.sedarplus.ca. Key Business Highlights On April 1, 2024, the Company entered into a contract research organization services agreement with Vivox Ltd. for animal experiments as part of the preclinical testing phase for the submission of an investigational new drug (“IND”) application to the United States Food and Drug Administration (the “FDA”). This is aimed at assessing the safety and efficacy of the ExoPTEN drug before proceeding to clinical trials involving human subjects, which is anticipated to commence in 2025. This engagement followed the completion of a pre-IND meeting with the FDA regarding the manufacturing, preclinical, and clinical development plan of ExoPTEN, NurExone’s inaugural ExoTherapy product, and the subsequent receipt of a written response from the FDA. On April 25, 2024, the Company's common shares were quoted on the Pink Sheets platform operated by OTC Markets Group Inc. ("OTC") under the symbol "NRXBF". On May 6, 2024, the Company's common shares were approved for uplisting from the OTC Pink Sheets to the OTCQB Venture Market, retaining the symbol "NRXBF", marking a significant milestone in the Company's growth and visibility within the financial community, including in the United States. In addition, the Company achieved Depository Trust Company (“DTC”) eligibility, which enhances the efficiency and cost-effectiveness of trading the Company's shares, facilitating better liquidity and broader access for investors. On June 11, 2023, the Company announced the expansion of its ExoPTEN patent coverage with an allowance of a patent application in Japan. This expands the Company's potential market to the far East. On June 11, 2024, the Company entered into an amending agreement with BullVestor Medien GmBH ("BullVestor"), modifying the original agreement dated in January 2024. Under the amending agreement, BullVestor continues to provide investor relations services to the Company until May 15, 2025. On June 21, 2024, the Company entered into a consulting agreement with Dr. Yona Geffen to support the Company’s preclinical and clinical activities. Dr. Geffen brings over two decades of extensive experience in leading clinical and drug development in the biotechnology and pharmaceutical industries. Growth Outlook for 2024 According to Chief Executive Officer Dr. Lior Shaltiel, “NurExone is making significant strides on the regulatory front, including the successful transfer of key manufacturing processes to a good manufacturing practice-compliant facility – an essential step toward clinical trials and commercial production. These efforts are being strengthened by our newly recruited consultant, Dr. Yona Geffen, a highly respected expert who has successfully guided companies through the regulatory landscape to commercialization. In parallel, the Company is collaborating with the Goldschleger Eye Institute at Sheba Medical Center, ranked by Newsweek as one of the top ten hospitals in the world, to study ExoPTEN for its potential in the multi-billion-dollar glaucoma marketi with promising preliminary results.” Second Quarter Fiscal 2024 Financial Results Research and development expenses, net, were US$0.51 million in the second quarter of 2024, compared to US$0.46 million in the same quarter in 2023. The increase was primarily due to higher subcontractor and materials expenses of US$0.07 million, partially offset by a governmental grant receipt of US$0.02 million.General and administrative expenses were US$0.81 million in the second quarter of 2024, compared to US$0.60 million in the same period in 2023. The rise was mainly attributed to an increase in professional and legal services expenses of US$0.22 million, partially offset by a US$0.01 million decrease in insurance expenses.Finance expenses were US$0.01 million in the second quarter of 2024, compared to finance income of US$0.02 million in the same period in 2023, primarily due to income from bank interest in the previous year.The net loss for the second quarter of 2024 was US$1.33 million, compared to a net loss of US$1.04 million in the second quarter of 2023. As of June 30, 2024, the Company held cash and cash equivalents totaling US$2.39 million, an increase from US$0.54 million as of December 31, 2023. The Company’s working capital also improved to US$2.24 million, up from US$0.07 million at the end of 2023. The increase in cash was primarily driven by the successful completion of a private placement in January 2024, which generated gross proceeds of approximately US$1.49 million, as well as the exercise of warrants in March 2024, yielding an additional US$2.93 million. These inflows were partially offset by a cash outflow of US$2.57 million related to operational activities. As of June 30, 2024, the Company had an accumulated deficit of US$16.30 million, compared to US$14.06 million as of December 31, 2023. Eran Ovadya, NurExone’s Chief Financial Officer, stated: “The Company remains committed to advancing research and development, as well as preparing ExoPTEN for clinical trials and commercial manufacturing. Additionally, through strategic guidance, we are aligning our business plan with current operations to ensure sustained growth and long-term success.” About NurExone Biologic Inc. NurExone Biologic Inc. is a TSX Venture Exchange (“TSXV”) listed pharmaceutical company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior ShaltielChief Executive Officer and DirectorPhone: +972-52-4803034Email: info@nurexone.com Thesis Capital Inc.Investment Relation - CanadaPhone: +1 905-347-5569Email: IR@nurexone.com Dr. Eva ReuterInvestment Relation - GermanyPhone: +49-69-1532-5857Email: e.reuter@dr-reuter.eu Allele Capital PartnersInvestment Relation - USPhone: +1 978-857-5075Email: aeriksen@allelecapital.com FORWARD-LOOKING STATEMENTS This press release contains certain “forward-looking statements”, that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to relating to the success of the partnership with Vivox Ltd.; the Company submitting an IND application with the FDA; the Company’s preclinical and clinical testing yielding their intended results; the Company proceeding to clinical trials on the timelines setout herein; the Company having sufficient funding for its operations; the Company having sustained growth and continued success; DTC eligibility facilitating better liquidity and broader access to investors; the Company expanding its potential market; BullVestor continuing to provide investor relations services to the Company on the timelines set out herein; the potential glaucoma market; the Company having adequate financing through the end of the year and well into 2025; the Company positioning itself for sustained growth and long-term success; and the NurExone platform technology offering novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including the general business and economic conditions of the industries and countries in which we operate; the general market conditions; the ability to secure additional funding; partnerships having their intended impact on the Company and its business; patents safeguarding NurExone’s technology; the Company’s drug products having its intended benefits and effects; the Company making progress through new partnerships and technologies to move towards commercialization of their products; the Company’s intellectual property and technology being novel and inventive; the intellectual property having the intended impact on the Company and its business; exosomes becoming an ideal and natural choice for drug delivery; the Company making advancements in the manufacturing process of exosomes; exosomes holding immense promise for regenerative medicine; the Company’s preclinical and clinical testing will yield their intended results; the Company will proceed to clinical trials on the timelines setout herein; the Company will have sufficient funding for its operations; the Company will have sustained growth and continued success; the Company will enter into new partnerships and/or licensing agreement; the Vivox Ltd. partnership will be successful; the company will submit an IND application with the; DTC eligibility will facilitate better liquidity and broader access to investors; the Company will expand its potential market; BullVestor will continue to provide investor relations services to the Company on the timelines set out herein; glaucoma market will grow; the Company will have adequate financing through the end of the year and well into 2025; the Company will position itself for sustained growth and long-term success; and the NurExone platform technology will offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to the Company’s early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; protection of the Company’s intellectual property; dependence on the Company’s strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials and/or on the timelines set out herein; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; the Company being unable to have sustained growth and/or continued success; risks that the Company’s intellectual property and technology won’t have the intended impact on the Company and/or its business; the Company’s inability to realize upon partnerships; risk that the Vivox Ltd. partnership will be unsuccessful; risk that the Company will be unable to submit or proceed with an IND application and/or it will be denied; risk that DTC eligibility won’t facilitate better liquidity and/or broader access to investors; the Company’s inability to expand its potential market; risk that BullVestor will be unable to continue to provide investor relations services to the Company on the timelines set out herein; risks associated with the size of the glaucoma market; risks that the Company will not have adequate financing through the end of the year and/or well into 2025; risks that the Company will be unable to position itself for sustained growth and long-term success; risk that the NurExone platform technology will be unable to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications; and the risks discussed under the heading “Risk Factors” on pages 29 to 36 of the Company’s Annual Information Form dated March 30, 2023, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law. Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. i Global Glaucoma Treatment Market Analysis by Spherical Insights LLP